JAK2 (Janus kinase 2)

Immune-based therapies, including brentuximab vedotin and PD-1 inhibitors, have shown promising activity, particularly in combination. MGZL remains a diagnostically challenging and therapeutically complex lymphoma with inferior outcomes compared with related mediastinal lymphomas. Advances in molecular profiling and immunotherapy offer promising avenues toward more personalized treatment; however, prospective clinical trials and international collaboration are urgently needed to establish evidence-based management strategies for this rare entity.

Experimental analysis showed that the CPO/PUE hydrogel could achieve sustained release of PUE, regulate the expression of muscle apoptosis-related proteins, inhibit the activation of the JAK2-STAT3 and NF-κB inflammatory pathways, and alleviate the suppression of the AKT-mTOR pathway. This delivery system effectively mitigates local muscle atrophy at the injection site in cancer cachexia, demonstrating a highly promising and significant therapeutic strategy.

This case suggests that JAK2 gene testing should be conducted for unexplained thrombocytosis; occult infection must be investigated when myeloproliferative neoplasm patients develop leukocytosis; maintaining therapeutic balance is crucial in the dual crisis of thrombosis and sepsis.

She was initially treated with low-dose acetylsalicylic acid, with partial improvement, but microvascular symptoms persisted, and platelet counts remained >1,000 × 10⁹/L. Hydroxyurea was initiated, leading to progressive platelet reduction and marked clinical benefit...Cytoreductive therapy may be indicated in cases with extreme thrombocytosis or refractory symptoms, and long-term follow-up is crucial to monitor disease evolution and treatment outcomes. This case highlights the need for multicenter studies and international registries to have pediatric-specific evidence that can better inform diagnostic and therapeutic strategies.

The authors apologize to the Editor of Oncology Reports and to the readership for any inconvenience caused. [Oncology Reports 45: 69, 2021; DOI: 10.3892/or.2021.8020].

Each of these tests showed sensitivities and specificities over 85% and an area under the curve of more than 0.9. SII, NLR, and PLR were all higher in PV than SP, suggesting that these biomarkers, particularly SII, might be helpful in the diagnosis of PV.

P=N/A, N=54, Not yet recruiting, Hospices Civils de Lyon

The case highlights the importance of distinguishing de novo lymphoid malignancies from MLN-eo-TK, especially when JAK2 rearrangements are detected. Recognition of the clonal myeloid component during or after lymphoid-directed therapy has important diagnostic and therapeutic implications, supporting the use of targeted JAK2 inhibition in addition to standard chemotherapy.

The JAK2 V617F mutation is a valuable target for MPNs screening. Clinicians can choose a more appropriate course of treatment and lower the risk of recurrent thrombosis if they promptly detect other prothrombotic states in the patient.

Hence, this minimalistic approach may be further validated in future studies. The online version contains supplementary material available at 10.1007/s12288-025-01968-2.

By disrupting the critical crosstalk between cancer cells and TAMs, TGP effectively remodels the inflammatory immune microenvironment, highlighting its potential as a promising therapeutic agent for GBC.